ABB: Q4 2022 Results
2.2.2023 08:46:00 EET | Business Wire | Press release
ABB (SWX:ABBN):
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230201005955/en/
|
KEY FIGURES |
|
|
|
|
|
|
|
|
||||
|
|
|
|
CHANGE |
|
|
CHANGE |
||||||
|
($ millions, unless otherwise indicated) |
Q4 2022 |
Q4 2021 |
US$ |
Comparable1 |
FY 2022 |
FY 2021 |
US$ |
Comparable1 |
||||
|
Orders |
7,620 |
8,257 |
-8% |
2% |
33,988 |
31,868 |
7% |
16% |
||||
|
Revenues |
7,824 |
7,567 |
3% |
16% |
29,446 |
28,945 |
2% |
12% |
||||
|
Gross Profit |
2,658 |
2,397 |
11% |
|
9,710 |
9,467 |
3% |
|
||||
|
as % of revenues |
34.0% |
31.7% |
+2.3 pts |
|
33.0% |
32.7% |
+0.3 pts |
|
||||
|
Income from operations |
1,185 |
2,975 |
-60% |
|
3,337 |
5,718 |
-42% |
|
||||
|
Operational EBITA1 |
1,146 |
988 |
16% |
28% 3 |
4,510 |
4,122 |
9% |
18% 3 |
||||
|
as % of operational revenues1 |
14.8% |
13.1% |
+1.7 pts |
|
15.3% |
14.2% |
+1.1 pts |
|
||||
|
Income from continuing operations, net of tax |
1,168 |
2,703 |
-57% |
|
2,637 |
4,730 |
-44% |
|
||||
|
Net income attributable to ABB |
1,132 |
2,640 |
-57% |
|
2,475 |
4,546 |
-46% |
|
||||
|
Basic earnings per share ($) |
0.61 |
1.34 |
-55%2 |
|
1.30 |
2.27 |
-43%2 |
|
||||
|
Cash flow from operating activities4 |
687 |
1,020 |
-33% |
|
1,287 |
3,330 |
-61% |
|
||||
|
Cash flow from operating activities in continuing operations |
720 |
1,033 |
-30% |
|
1,334 |
3,338 |
-60% |
|
||||
|
1 For a reconciliation of non-GAAP measures, see “supplemental reconciliations and definitions” in the attached Q4 2022 Financial Information. |
||||||||||||
|
2 EPS growth rates are computed using unrounded amounts. 2021 numbers include the impact related to the divestment of Mechanical Power Transmission. |
||||||||||||
|
3 Constant currency (not adjusted for portfolio changes). |
||||||||||||
|
4 Amount represents total for both continuing and discontinued operations. |
||||||||||||
“2022 was another successful year for ABB, including a further streamlining of our business portfolio and achieving our margin target earlier than expected. We have made ABB more resilient. In 2023, regardless of current market uncertainty, we want to show that we can continuously deliver an Operational EBITA margin of at least 15%.”
Björn Rosengren, CEO
CEO summary
In the fourth quarter of 2022, we improved comparable orders and revenues, we increased our Operational EBITA by 16%, raised our Operational EBITA margin by 170 basis points and lifted ROCE to 16.5% for 2022, to within our target range. All in all, this was a good achievement in my view.
Customer activity improved slightly or remained stable in most customer segments, except for declines related to residential construction and discrete manufacturing. The market outlook for discrete manufacturing remains solid, although the fourth quarter was adversely impacted by customers normalizing order patterns following a period of pre-ordering triggered by the long delivery lead times in a strained value chain. This weighed on order intake in Robotics & Discrete Automation, while the other three business areas remained stable or increased comparable orders. Revenues were strong and increased by 3% (16% comparable). The Americas region was the growth engine for orders, while Europe reversed and Asia, Middle East and Africa remained overall largely stable despite a decline in China. The escalating Covid-related situation in China somewhat slowed down local business activity towards the end of the period. Our priority is to keep our people safe.
Our strong price execution combined with increased volumes supported the higher gross margin and drove the improvement of 170 basis points in the Operational EBITA margin to 14.8%, the strongest fourth quarter margin in several years. This resulted in 2022 being a record year for ABB, in recent history, with an Operational EBITA margin of 15.3%. We achieved good price management, executed well on increased volumes with some additional support from unusually low corporate costs. I am pleased how the divisions managed challenges like supply chain constraints, a tight labor market, Covid-related lock downs in China and a high inflationary environment.
Cash flow of $687 million in the quarter is the one area which did not quite meet our expectations as the depletion of net working capital was slower than anticipated. This will be an important focus area for us near term as we deliver against our high order backlog. As earlier announced, the finalization of the Kusile-related issues weighed on cash flow by approximately $315 million, while the closing of the divestment of Power Grids generated a net cash contribution in investing activities of $1.4 billion.
We remain committed to our plans to separately list our E-mobility business, subject to constructive market conditions. Meanwhile, we have closed by the end of January the pre-IPO private placement of approximately CHF525 million for newly issued shares to new minority investors representing approximately 20% ownership of the E-mobility business. The proceeds will be used to capture E-mobility’s growth potential through organic and M&A investments in hardware and software.
Just after the close of the fourth quarter, we progressed with the final part of our announced divisional exits by signing an agreement to divest the Power Conversion division in the Electrification business area. From here on, we will continue to review our business portfolio on a product group level within our current divisions. One example is our decision to initiate the exit of the emergency lighting business within the Smart Buildings division in the Electrification business area during 2023.
By partnering with the Swedish mining and smelting company Boliden to build a strategic co-operation to use low carbon footprint copper in our electromagnetic stirring (EMS) equipment and high-efficiency electric motors, we took another step towards our 2030 target of having a circular approach in at least 80 percent of our products and solutions. The aim is to reduce greenhouse gas (GHG) emissions while driving the transition to a more circular economy.
Looking into 2023, we currently do not anticipate a major set-back in demand, although the high inflationary environment adds uncertainty. Comparable order growth, at least in the first half of the year, should be somewhat hampered by last year’s very high order level coupled with a normalization of customers’ order pattern after a period of pre-ordering in times of a strained value chain. I expect comparable revenue growth to be above 5%, supported by backlog execution. Cash flow should benefit from us working down the net working capital, and we should also have less adverse items impacting comparability. I view 2023 as a good opportunity for ABB to prove that we can continuously deliver an annual Operational EBITA margin of at least 15%.
Considering improving performance, robust cash flow and a solid balance sheet, the Board of Directors proposes an ordinary dividend of CHF0.84 per share. Up from CHF0.82 in the previous year and in line with the long-term ambition of a rising sustainable dividend per share over time, while still prioritizing a solid balance sheet to support our growth ambitions. We plan to continue with share buybacks for full year of 2023.
Björn Rosengren
CEO
Outlook
In the first quarter of 2023, we anticipate double-digit comparable revenue growth to support some improvement in the Operational EBITA margin, year-on-year.
In full-year 2023, despite current market uncertainty, we anticipate comparable revenue growth to be above 5% and we expect to again achieve our long-term target of Operational EBITA margin of at least 15%.
The complete press release including the appendices is available at www.abb.com/news.
ABB (ABBN: SIX Swiss Ex) is a technology leader in electrification and automation, enabling a more sustainable and resource-efficient future. The company’s solutions connect engineering know-how and software to optimize how things are manufactured, moved, powered and operated. Building on more than 130 years of excellence, ABB’s ~105,000 employees are committed to driving innovations that accelerate industrial transformation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230201005955/en/
Contact information
ABB Ltd
Affolternstrasse 44
8050 Zurich
Switzerland
Media Relations
+41 43 317 71 11
media.relations@ch.abb.com
Investor Relations
+41 43 317 71 11
investor.relations@ch.abb.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
